DiamiR, future Aptorum subsidiary, collaborates with AlzLabs on Alzheimer's disease biomarkers
APM sits 39% above its 52-week low of $0.65.
Summary
Aptorum Group announced a collaboration between DiamiR Biosciences, its soon-to-be subsidiary, and AlzLabs Precision Diagnostics to develop blood-based biomarkers for Alzheimer's disease. This partnership expands DiamiR's diagnostic pipeline, which will become part of the combined company's assets. The news follows the recent shareholder approval of Aptorum Group's reverse merger with DiamiR, expected to close before fiscal 2027. This development could add value to the merged entity, particularly in light of Aptorum Group's previous going concern warning.
At the time of this announcement, APM was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.65 to $4.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.